A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Roche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis - European Pharmaceutical Review
Roche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis - European Pharmaceutical Review
Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial - Fierce Biotech
Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial - Fierce Biotech
Genentech cut at least 489 jobs last year, new filing reveals - Fierce Biotech
Genentech cut at least 489 jobs last year, new filing reveals - Fierce Biotech
Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech
Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech
Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News
Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News
Roche’s 2025 profit blunted by weakened US dollar - Medical Device Network
Roche’s 2025 profit blunted by weakened US dollar - Medical Device Network
Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology
Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech
Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine
How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine
Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech
Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech
Roche announces positive phase II results for experimental obesity drug - wkzo.com
Roche announces positive phase II results for experimental obesity drug - wkzo.com
Is Roche Becoming a Contender in the Obesity Drug Market? - Healthcare Digital
Is Roche Becoming a Contender in the Obesity Drug Market? - Healthcare Digital
Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com
Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com
Anthropic, Roche & NVIDIA: This Week's Top Stories - Healthcare Digital
Anthropic, Roche & NVIDIA: This Week's Top Stories - Healthcare Digital
Roche: Making Preventative Healthcare Accessible to All - Healthcare Digital
Roche: Making Preventative Healthcare Accessible to All - Healthcare Digital
Former Roche oncology head turns to Tubulis—Chutes & Ladders - fiercebiotech.com
Former Roche oncology head turns to Tubulis—Chutes & Ladders - fiercebiotech.com
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page